



Educational Autumn Meeting 2008

on

Advances in Cardiovascular Drug Therapy

Cardiovascular protection by cardiovascular drug therapy

This meeting is sponsored through an unrestricted educational grant provided by Takeda Pharmaceuticals Europe Ltd

Venue: Vienna, AT, Vienna Hilton Hotel

Date: Saturday 29 – Sunday 30, November 2008

 Session 1:
 Saturday
 15:00 – 17:00

 Session 2:
 Saturday
 17:30 – 19:00

 Session 3:
 Sunday
 08:30 – 10:00

 Session 4:
 Sunday
 10:30 – 12:00

Address for correspondence:

Dr Kurt Stoschitzky, FESC

Working Group on Cardiovascular Pharmacology and Drug Therapy of the European Society of Cardiology

Universitätsklinik für Innere Medizin

Abteilung für Kardiologie

Auenbruggerplatz 15

A-8036 Graz, Austria

Phone: +43-316-385-80261 Fax: +43-316-385-3733

e-mail: kurt.stoschitzky@meduni-graz.at

Programme

Saturday, November 29, 2008

15:00 - 17:00:

Introduction to the field

Chair: Faiez Zannad (Nancy, FR), Kurt Stoschitzky (Graz, AT)

15:00 – 16:00: Zeljko Reiner (Zagreb, HR)

Cardiovascular prevention under the burden of cardiovascular diseases: What should be done and what can be done?

16:00 – 16:30: Ferenc Follath (Zürich, CH) Ethical considerations of cardiovascular risk reduction

16:30 – 17:00: Stevo Julius (Ann Arbor, MI)

Clinical trials in arterial hypertension – the past and the future

17:00 – 18:00: *Coffee break*

18:00 - 19:00:

Treatment of hyperlipidaemia

Chair: Dan Atar (Oslo, NO), Keld Kjeldsen (Kobenhavn, DK)

18:00 – 19:00: Heinz Drexel (Feldkirch, AT)

Statins, Fibrates, Nicotinic acid, Cholesterol absorption inhibitors, Anion-exchange resins, Omega-3 fatty acids – which drugs for which patients?

19:30:

Extraordinary Nucleus Meeting

Working Group on Cardiovascular Pharmacology and Drug Therapy

Sunday, November 30, 2008

8:30 - 10:00:

Treatment of arterial hypertension (Focus on candesartan)

8:30 – 10:00: **Chair**:

Wiek van Gilst (Groningen, NL), Stefan Agewall (Stockholm, SE)

8:30 – 9:00: Roland Asmar (Paris, FR)

Blood-pressure control and beyond – are all ARBs equal?

9:00 – 9:30: Ulrike Steckelings (Berlin, DE)

The evolving story of the RAAS in hypertension, diabetes and CV disease – moving from macrovascular to microvascular targets

9:30 – 10:00: Massimo Porta (Torino, IT)

The future of managing microvascular complications in diabetes – what does DIRECT tell us?

10:00 – 10:30: *Coffee break*

10:30 - 12:00

Treatment of diabetes mellitus (Focus on pioglitazone)

10:30 – 12:00: **Chair**: Maria Angeles Alonso Garcia (Madrid, ES), Franco Naccarella (Bologna, IT), Brian Prichard (London, UK)

10:30 – 11:00: Jochen Seufert (Freiburg, DE)

Glycaemic durability and control in Type 2 Diabetes: recent insights

11:00 – 11:30: Bruno Vergès (Dijon, FR)

Lipid modification in diabetes: The role of LDL and HDL

11:30 – 12:00: D John Betteridge (London, UK)

CHICAGO, PERISCOPE and PROactive:

CV risk modification in diabetes with pioglitazone



Get actively involved...

... and become a member of the

ESC Working Group on Cardiovascular Pharmacology & Drug Therapy

and contribute to research and education in your area of expertise:

- Network and exchange knowledge with your peers
- Help to define strategies for treatment in your sector
- Contribute to and benefit from educational activities
- Stay abreast of advances and developments in your field

Apply for membership, and enjoy exclusive advantages:

- Regular informations on the Working Group's activities and meetings
- Discount prices on the ESC Educational Products
- Exclusive subscription rates for all ESC Journals (including the *European Heart Journal*)
- A free set of the latest ESC Pocket Guidelines on the occasion of each year's ESC Annual Congress

Get more informations and your online application form at www.escardio.org/pharmacology